Known targets — ChEMBL curated mechanism
CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8
The experimentally established mechanism targets of Pregabalin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 known ✓ | P54289 | 2/20 | 0.59 |
| ▸ | CACNB3 known ✓ | P54284 | 1/20 | 0.59 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.59 |
| ▸ | CACNA2D2 known ✓ | Q9NY47 | 1/20 | 0.59 |
| ▸ | PGR | P06401 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pregabalin SCHEMBL3668928 | 0.89 | CACNA2D1 (0.63) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL3667736 | 0.81 | CACNA2D1 (0.85) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL10771841 | 0.81 | CYP2D6 (0.49) | KDM4ECYP1A2CYP2D6MAPK1CYP2C9 | |
| SCHEMBL7068022 | 0.81 | CYP2D6 (0.43) | KDM4ECYP1A2CYP2D6MAPK1CYP2C9 | |
| SCHEMBL6534817 | 0.80 | KDM4E (0.46) | KDM4ECYP1A2CYP2D6MAPK1CYP2C9 | |
| SCHEMBL5846628 | 0.80 | KDM4E (0.51) | KDM4ECYP1A2CYP2D6MAPK1CYP2C9 | |
| SCHEMBL2853513 | 0.80 | KDM4E (0.51) | KDM4ECYP1A2CYP2D6MAPK1CYP2C9 | |
| Pregabalin SCHEMBL3672469 | 0.79 | CACNA2D1 (0.81) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Glycine SCHEMBL5685912 | 0.77 | CYP2C9 (0.51) | KDM4ECYP1A2CYP2D6MAPK1CYP2C9 | |
| Leucine SCHEMBL30462445 | 0.77 | SLC7A5 (0.55) | CYP1A2CYP2D6MAPK1CYP2C9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242737-A1 | PREGABALIN SALTS | Synthon B.V. (NL) | 2010-10-27 | — | — | EP | claimed |
| WO-2009080365-A1 | PREGABALIN SALTS | SYNTHON B.V. (NL) | 2009-07-02 | — | — | WO | claimed |
| US-20090170945-A1 | PREGABALIN SALTS | SYNTHON BV (NL) | 2009-07-02 | — | — | US | claimed |
| US-20200222544-A1 | LINEAR POLYSACCHARIDE BASED FILM PRODUCTS | AQUESTIVE THERAPEUTICS, INC. | 2020-07-16 | — | — | US | disclosed |
| US-20180280518-A1 | LINEAR POLYSACCHARIDE BASED FILM PRODUCTS | AQUESTIVE THERAPEUTICS, INC. | 2018-10-04 | — | — | US | disclosed |
| US-20170360942-A1 | LINEAR POLYSACCHARIDE BASED FILM PRODUCTS | MONOSOL RX, INC. | 2017-12-21 | — | — | US | disclosed |
| EP-3229778-A1 | LINEAR POLYSACCHARIDE BASED FILM PRODUCTS | MonoSol Rx LLC (US) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016094567-A1 | LINEAR POLYSACCHARIDE BASED FILM PRODUCTS | MONOSOL RX, LLC (US) | 2016-06-16 | — | — | WO | disclosed |
| EP-2242737-A1 | PREGABALIN SALTS | Synthon B.V. (NL) | 2010-10-27 | — | — | EP | disclosed |
| WO-2010115612-A2 | PREGABALIN COMPOSITIONS | SYNTHON B.V. (NL) | 2010-10-14 | — | — | WO | disclosed |
| WO-2009080365-A1 | PREGABALIN SALTS | SYNTHON B.V. (NL) | 2009-07-02 | — | — | WO | disclosed |
| US-20090170945-A1 | PREGABALIN SALTS | SYNTHON BV (NL) | 2009-07-02 | — | — | US | disclosed |
| US-20090170945-A1 | PREGABALIN SALTS | SYNTHON BV (NL) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170945-A1 | PREGABALIN SALTS | GABRG2, SLC6A13, GABRG1 | CACNA2D1 136/4885CACNB3 116/4885CACNA1C 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.